The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
Database shows that researchers with retracted papers had higher self-citation rates and published more than those without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback